Prothena Corporation plc: Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
VITAL study 9-month results expected to be presented at a medical conference in 2021
Prasinezumab
Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference
PRX004
PRX005
IND expected by 3Q 2021
$80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021
PRX012, a potential treatment for Alzheimer's disease, is a high affinity monoclonal antibody targeting a key epitope within the N-terminus of Aß
IND expected by 1Q 2022
Upcoming Investor Conferences
Members of the senior management team will present and participate in investor meetings at the following upcoming investor conferences: